

# Hospital Compare Quality Measure Results for CAHs, Q2 2014 - Q1 2015

Michelle Casey, MS; Tami Swenson, PhD; Alex Evenson, MA University of Minnesota

#### INTRODUCTION

This report summarizes reporting rates and performance among all U.S. Critical Access Hospitals (CAHs) on Hospital Compare inpatient and outpatient process of care and structural measures for April 2014 through March 2015 (Q2 2014-Q1 2015). The Flex Monitoring Team also produces state-specific CAH reports with more detailed results.

**Flex Monitoring Team** 

**BACKGROUND** 

Since 2004, acute care hospitals paid under the Medicare Prospective Payment System (PPS) have had a financial incentive to publicly report quality measure data on the Centers for Medicare and Medicaid Services' (CMS) Hospital Compare website. Although Critical Access Hospitals (CAHs) do not face the same financial incentives as PPS hospitals to participate, the Hospital Compare initiative provides an important opportunity for CAHs to publicly report, assess, and improve their performance on national standards of care.


#### **APPROACH**

For the inpatient and outpatient process of care measures (except the median time process measures), the percentages of patients that received recommended care were calculated by dividing the total number of patients in all CAHs nationally who received the recommended care by the total number of eligible patients in all CAHs nationally for each measure. Median scores for the median time measures were calculated by arrang-

ing the median times by quarter for all CAHs nationally from the lowest time to the highest time by hospital, and selecting the middle value based on the number of patients. On the median time measures, lower scores, indicating shorter median times, are better. For each structural measure, the percentages of CAHs that reported no data and those that reported yes or no on each measure were calculated.

The Hospital Compare data in this report include several measures that are also measures for the Medicare

Figure 1. CAH Participation in Hospital Compare, 2011 - 2015 (N=1,336<sup>a</sup>)



<sup>a</sup>N value refers to most recent data (Q2 2014 - Q1 2015). Prior years' N values are as follows: 2011 - 1,328; Q2 2012 - Q1 2013, 1,332; and Q2 2013 - Q1 2014, 1,338.



Beneficiary Quality Improvement Project (MBQIP). Although the majority of CAHs report data on these measures to both Hospital Compare and MBQIP, the data in this report may differ from MBQIP reports because some CAHs only report data to one of these programs.

#### **RESULTS**

For Q2 2014-Q1 2015, 84.7% of CAHs reported data to Hospital Compare on at least one inpatient measure, while 50.7% of CAHs reported data on at least one outpatient measure (Figure 1). Both the inpatient and outpatient reporting percentages represent slight decreases from the previous year. Figure 2 shows state rankings on inpatient and outpatient reporting rates.

Tables 1 and 2 display the number of CAHs reporting and performance on each of the inpatient and outpatient process-of-care measures (except the median time process measures) for Q2 2014 through Q1 2015 discharges for CAHs nationally and for the 45 Flex states. Table 3 displays the national and state results for the median time measures. Nationally, more than three-fourths of CAHs did not report structural quality measure data. Table 4 provides results for CAHs nationally that reported data between Q2 2014 and Q1 2015.

The inpatient heart failure and pneumonia measures, which are the two quality measures with the largest number of CAHs reporting during this time period, are no longer included in Hospital Compare. Several other

inpatient measures reported by a significant number of CAHs, including surgical care improvement and stroke measures, have also been removed from Hospital Compare. Thus, the percentage of CAHs reporting inpatient measures may decline further in the future.

#### **TOOLS AND RESOURCES**

The Flex Monitoring Team (FMT) provides free access to all publications and presentations on our website, <a href="www.flexmonitoring.org">www.flexmonitoring.org</a>, including a series of policy briefs on evidence-based QI programs and strategies that could be implemented by CAHs.

The <u>Technical Assistance Services Center (TASC)</u> provides resources for State Flex Programs and CAHs on their website.

For profiles of State Flex Programs, State Contacts, and examples of Flex activities to support quality improvement, visit <a href="http://www.ruralcenter.org/tasc/flex-profile">http://www.ruralcenter.org/tasc/flex-profile</a>


For resources focused on the Medicare Beneficiary Quality Improvement Program (MBQIP), visit <a href="https://www.ruralcenter.org/tasc/mbqip">https://www.ruralcenter.org/tasc/mbqip</a>.

#### **REFERENCES**

1. The Flex Monitoring Team has published national Hospital Compare reports since 2006. All are available for download at <a href="http://www.flexmonitoring.org/publications/annualhospital-compare-results/">http://www.flexmonitoring.org/publications/annualhospital-compare-results/</a>.



Figure 2. State Rankings of CAH Reporting Rates for Hospital Compare Inpatient and **Outpatient Quality Measures** 





# Table 1. Inpatient Process of Care Results for Patients Discharged from Reporting CAHs

		CAHs reporting	CAH performance <sup>a</sup>
AMI-7a	Fibrinolytic therapy received within 30 minutes of hospital arrival	8	20.0
HF-2	Evaluation of LVS function	1042	88.5
IMM-2 <sup>†</sup>	Immunization for influenza	542	90.9
OP-27/IMM-3 <sup>†</sup>	Healthcare workers given influenza vaccination	373	87.5
PC-01 <sup>‡</sup>	Early elective delivery (lower is better)	135	8.8
PN-6	Initial antibiotic selection for pneumonia patient	1069	89.7
SCIP-Card-2	Surgery patients who received perioperative beta blocker	418	95.4
SCIP-Inf-1	Preventative antibiotic(s) 1 hour before incision	478	95.9
SCIP-Inf-2	Received appropriate preventative antibiotic(s)	477	97.4
SCIP-Inf-3	Preventative antibiotic(s) stopped within 24 hours after surgery	474	97.0
SCIP-Inf-9	Urinary catheter removed 1st / 2nd day after surgery	447	97.4
SCIP-VTE-2	Surgery patients who received appropriate VTE prophylaxis	493	99.1
STK-1‡	VTE prophylaxis	312	89.2
STK-2	Discharged on antithrombotic therapy	283	94.7
STK-3	Anticoagulation therapy for atrial fibrillation/flutter	166	91.8
STK-4	Thrombolytic therapy	105	10.9
STK-5	Antithrombotic therapy by end of hospital day 2	280	93.2
STK-6	Discharged on statin medication	294	79.3
STK-8‡	Stroke education	238	81.2
STK-10	Assessed for rehabilitation	294	95.4
VTE-1‡	Venous thromboembolism prophylaxis	364	89.4
VTE-2‡	ICU venous thromboembolism prophylaxis	165	93.1
VTE-3‡	Anticoagulation overlap therapy	313	90.5
VTE-4	Unfractionated heparin with dosages/platelet count monitoring	145	98.3
VTE-5	Warfarin therapy discharge instructions	399	89.0
VTE-6	Incidence of potentially-preventable VTE (lower is better)	91	10.1

<sup>&</sup>lt;sup>a</sup>Expressed as a percentage of patients receiving recommended care (lower is better for PC-01 and VTE-6), except for OP-27/IMM-3, which is the percentage of healthcare workers immunized.

<sup>†</sup>MBQIP core measure (this table shows Hospital Compare data)

<sup>&</sup>lt;sup>‡</sup>MBQIP additional improvement measure (this table shows Hospital Compare data)



# Table 2. Outpatient Process of Care Results for Patients Discharged from Reporting CAHs

		CAHs reporting	CAH performance <sup>a</sup>
0P-2 <sup>†</sup>	Fibrinolytic therapy received within 30 minutes	290	52.2
0P-4 <sup>†</sup>	Aspirin at arrival	644	96.1
0P-22 <sup>†</sup>	Patient left without being seen (lower is better)	166	1.0
OP-23‡	Received head CT scan interpretation within 45 minutes of arrival	303	58.0

<sup>&</sup>lt;sup>a</sup>Expressed as a percentage of patients receiving recommended care (lower is better for OP-22).

# Table 3. Median Time to Patients Receiving Recommended Care at CAHs

Note: Lower scores are better for all median time measures		CAHs reporting	CAH performance <sup>a</sup>
ED-1b‡	Median time from ED admission to ED departure for admitted patients		217
ED-2b‡	Admit decision time to ED departure time for admitted patients	509	56
0P-1 <sup>†</sup>	Median time to fibrinolysis	241	29
OP-3b <sup>†</sup>	Median time to transfer to another facility for acute coronary intervention	368	67
0P-5 <sup>†</sup>	Median time to ECG	645	7
OP-18b <sup>†</sup>	Median time from ED arrival to ED departure for discharged patients	336	104
0P-20 <sup>†</sup>	Median time from door to diagnostic evaluation	341	18
0P-21 <sup>†</sup>	Median time to pain management for long bone fracture	339	45

<sup>&</sup>lt;sup>a</sup>Median number of minutes to receiving recommended care (lower is better for all median time measures)

# Table 4. Structural Quality Measures Reported by CAHs

		No Data (#CAHs / %)	No (#CAHs / %)	Yes (#CAHs / %)
0P-12	Ability to receive lab data directly to certified EHR	1,145 (85.7%)	27 (2.0%)	164 (12.3%)
0P-17	Ability to track clinical results between visits	1,150 (86.1%)	39 (2.9%)	147 (11.0%)
0P-25‡	Use of safe surgery checklist: outpatient	1,153 (86.3%)	15 (1.1%)	168 (12.6%)
SM-3	Nursing care registry	1,122 (84.0%)	158 (11.8%)	56 (3.8%)
SM-4	General surgery registry	1,122 (84.0%)	201 (15.0%)	13 (1.0%)
SM-5	Use of safe surgery checklist: inpatient	1,122 (84.0%)	27 (2.0%)	187 (14.0%)

<sup>&</sup>lt;sup>‡</sup>MBQIP additional improvement measure (this table shows Hospital Compare data)

<sup>&</sup>lt;sup>†</sup>MBQIP core measure (this table shows Hospital Compare data)

<sup>&</sup>lt;sup>‡</sup>MBQIP additional improvement measure (this table shows Hospital Compare data)

<sup>†</sup>MBQIP core measure (this table shows Hospital Compare data)

<sup>&</sup>lt;sup>‡</sup>MBQIP additional improvement measure (this table shows Hospital Compare data)



#### **DEFINITIONS OF MEASURES**

Note: higher numbers reflect better performance, except where indicated below.

- AMI-7a: Fibrinolytic therapy received within 30 minutes of arrival Acute Myocardial Infarction (AMI) patients receiving fibrinolytic therapy during the hospital stay and having a time from hospital arrival to fibrinolysis of 30 minutes or less.
- ED-1b: Admit Decision Time to Emergency Department (ED) Departure Time for Admitted Patients median time from admit decision time to time of departure from the ED for patients admitted to inpatient status. (A lower number is better.)
- ED-2b:Median Time from Emergency Department (ED) Arrival to ED Departure for Admitted Patients median time from ED arrival to time of departure from the ED for patients admitted to the facility from the ED (A lower number is better.)
- HF-2: Evaluation of Left Ventricular Systolic (LVS) Function heart failure patients with documentation in the hospital record that an evaluation of the LVS function was performed before arrival, during hospitalization, or is planned for after discharge.
- IMM-2: Influenza Vaccination This prevention measure addresses acute care hospitalized inpatients age 6 months and older who were screened for seasonal influenza immunization status and were vaccinated prior to discharge if indicated. The numerator captures two activities: screening and the intervention of vaccine administration when indicated. As a result, patients who had documented contraindications to the vaccine, patients who were offered and declined the vaccine, and patients who received the vaccine during the current year's influenza season but prior to the current hospitalization are captured as numerator events.
- OP-1: Median Time to Fibrinolysis median time from arrival to fibrinolysis for patients that received

fibrinolysis. (A lower number is better.)

- OP-2: Fibrinolytic therapy received within 30 minutes of arrival Acute Myocardial Infarction (AMI) patients receiving fibrinolytic therapy during the hospital stay and having a time from hospital arrival to fibrinolysis of 30 minutes or less.
- OP-3b: Median Time to Transfer to Another Facility for Acute Coronary Intervention Median number of minutes before outpatients with heart attack who needed specialized care were transferred to another hospital. (A lower number is better.)
- **OP-4:** Aspirin at arrival Acute Myocardial Infarction (AMI) patients without aspirin contraindications who received aspirin within 24 hours before or after hospital arrival.
- OP-5: Median Time to echocardiogram (ECG)

   median number of minutes before outpatients
   with heart attack (or with chest pain that suggests
   a possible heart attack) got an ECG. (A lower number is better).
- OP-12: Ability to Receive Lab Data Directly to Electronic Health Record (EHR) the ability for providers with Health Information Technology (HIT) to receive laboratory data directly into their ONC-certified EHR system as discrete searchable data.
- OP-17: Ability to Track Clinical Results between Visits the ability for a facility to track pending laboratory tests, diagnostic studies, or patient referrals through the ONC-certified Electronic Health Record (EHR) system.
- OP-18b: Median Time from Emergency Department (ED) Arrival to ED Departure for Discharged Patients - median time from ED arrival to time of departure from the ED for patients discharged from the ED (a lower number is better).
- OP-20: Door to Diagnostic Evaluation by Qualified Medical Personnel - median time from Emergency Department (ED) arrival to provider contact for ED patients (a lower number is better).

- OP-21: Median Time to Pain Management for Long Bone Fracture median time from Emergency Department (ED) arrival to time of initial oral or parenteral pain medication administration for ED patients with a principal diagnosis of long bone fracture (a lower number is better).
- OP-22: Left Without Being Seen percent of patients who leave the Emergency Department (ED) without being evaluated by a physician, advanced practice nurse (APN), or physician's assistant (PA). (A lower number is better.)
- OP-23: Head CT or MRI Scan Results for Acute Ischemic Stroke or Hemorrhagic Stroke Patients who Received Head CT or MRI Scan Interpretation Within 45 Minutes of Emergency Department (ED) Arrival percentage of acute ischemic stroke or hemorrhagic stroke patients who arrive at the ED within 2 hours of the onset of symptoms who have a head CT or MRI scan performed during the stay and have interpretation of the CT or MRI scan within 45 minutes of arrival.
- OP-25: Use of Safe Surgery Checklist (Outpatient)

   whether or not a facility used a checklist for outpatient surgical procedures during each of the three critical perioperative periods (prior to administration of anesthesia, prior to skin incision, and closure of incision / prior to patient leaving the operating room).
- OP-27 / HMM-3: Health Care Workers Given Influenza Vaccination Facilities must report vaccination data for three categories of Healthcare Personnel (HCP): employees on payroll; licensed independent practitioners (who are physicians, advanced practice nurses, and physician assistants affiliated with the hospital and not on payroll); and students, trainees, and volunteers aged 18 or older. Only HCP physically working in the facility for at least one day or more between October 1 and March 31 should be counted. Data on vaccinations received at the facility, vaccinations received outside of the facility, medical contraindications, and declinations are reported for the three categories of HCP.

- PC-01: Elective Delivery patients with elective vaginal deliveries or elective cesarean sections at greater than or equal to 37 and less than 39 weeks of gestation completed (a lower number is better).
- PN-6: Most Appropriate Initial Antibiotics immunocompetent patients with pneumonia who receive an initial antibiotic regimen that is consistent with current guidelines.
- SCIP-Inf-1: Prophylactic Antibiotic Received within One Hour Prior to Surgical Incision surgical patients who received prophylactic antibiotics within 1 hour prior to surgical incision.
- SCIP-Inf-2: Prophylactic Antibiotic Selection for Surgical Patients surgical patients who received the recommended antibiotics for their particular type of surgery.
- SCIP-Inf-3: Prophylactic Antibiotics Discontinued Within 24 Hours After Surgery End Time surgical patients whose prophylactic antibiotics were discontinued within 24 hours after surgery end time.
- SCIP-Card-2: Surgery Patients on a Beta Blocker Prior to Arrival Who Received a Beta Blocker During the Perioperative Period surgery patients who were taking heart drugs called beta blockers before coming to the hospital, who were kept on the beta blockers during the period just before and after their surgery.
- SCIP-VTE-2: Surgery Patients Who Received Appropriate Venous Thromboembolism (VTE) Prophylaxis within 24 Hours Prior to Surgery to 24 Hours After Surgery surgery patients who received appropriate VTE prophylaxis within 24 hours prior to surgical incision time to 24 hours after surgery end time.
- SM-3: Nursing Care Registry participation in a systematic clinical database for nursing-sensitive care
- SM-4: General Surgery Registry participation in a systematic clinical database for general surgery

- SM-5: Use of Safe Surgery Checklist (inpatient) whether or not a facility used a checklist for inpatient surgical procedures during each of the three critical perioperative periods (prior to administration of anesthesia, prior to skin incision, and closure of incision / prior to patient leaving the operating room).
- STK-1: Venous Thromboembolism (VTE) Prophylaxis ischemic and hemorrhagic stroke patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after hospital admission.
- STK-2: Discharged on Antithrombotic Therapy ischemic stroke patients prescribed antithrombotic therapy at hospital discharge.
- STK-3: Anticoagulation Therapy for Atrial Fibrillation/Flutter ischemic stroke patients with atrial fibrillation/flutter who are prescribed anticoagulation therapy at hospital discharge.
- STK-4: Thrombolytic Therapy acute ischemic stroke patients who arrive at this hospital within two hours of time last known well and for whom intravenous tissue plasminogen activator (IV tPA) was initiated at this hospital within three hours of time last known well.
- STK-5: Antithrombotic Therapy By End of Hospital Day 2 ischemic stroke patients administered antithrombotic therapy by the end of hospital day two.
- STK-6: Discharged on Statin Medication ischemic stroke patients with low-density lipoprotein (LDL) cholesterol levels greater than or equal to 100 mg/dL, or LDL not measured, or who were on a lipid-lowering medication prior to hospital arrival are prescribed statin medication at hospital discharge.
- STK-8: Stroke Education ischemic or hemorrhagic stroke patients or their caregivers who were given educational materials during the hospital stay addressing all of the following: activation of emergency medical system, need for follow-up after discharge, medications prescribed at discharge, risk

- factors for stroke, and warning signs and symptoms of stroke.
- STK-10: Assessed for Rehabilitation ischemic or hemorrhagic stroke patients who were assessed for rehabilitation services.
- VTE-1: Venous Thromboembolism (VTE) Prophylaxis the number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after hospital admission or surgery end date for surgeries that start the day of or the day after hospital admission.
- VTE-2: Intensive Care Unit (ICU) Venous Thromboembolism (VTE) Prophylaxis number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after the initial admission (or transfer) to the ICU or surgery end date for surgeries that start the day of or the day after ICU admission (or transfer).
- VTE-3: Venous Thromboembolism (VTE) Patients with Anticoagulation Overlap Therapy the number of patients diagnosed with confirmed VTE who received an overlap of parenteral (intravenous or subcutaneous) anticoagulation and warfarin therapy. Patients who received less than five days of overlap therapy should be discharged on both medications or have a reason for discontinuation of parenteral therapy. Overlap therapy should be administered for at least five days with an international normalized ratio (INR) greater than or equal to two prior to discontinuation of the parenteral anticoagulation therapy, discharged on both medications, or have a reason for discontinuation of parenteral therapy.
- VTE-4: Venous Thromboembolism (VTE) Patients Receiving Unfractionated Heparin (UFH) with Dosages/Platelet Count Monitoring by Protocol or Nomogram the number of patients diagnosed with confirmed VTE who received intravenous (IV) UFH therapy dosages and had their platelet counts monitored using defined parameters such as a nomogram or protocol.



- VTE-5: Venous Thromboembolism (VTE) Warfarin Therapy Discharge Instructions the number of patients diagnosed with confirmed VTE that are discharged to home, home care, court/law enforcement or home on hospice care on warfarin with written discharge instructions that address all four criteria: compliance issues, dietary advice, follow-up monitoring, and information about the potential for adverse drug reactions/interactions.
- VTE-6: Hospital Acquired Potentially-Preventable Venous Thromboembolism (VTE) the number of patients diagnosed with confirmed VTE during hospitalization (not present at admission) who did not receive VTE prophylaxis between hospital admission and the day before the VTE diagnostic testing order date (a lower number is better).

## For detailed measure specifications:

- Specifications Manual for National Hospital Inpatient Quality Measures http://bit.ly/InpManual, accessed March 3, 2015
- Specifications Manual for National Hospital Outpatient Quality Measures http://bit.ly/OutpManual, accessed March 3, 2015
- Prenatal measure specifications
   http://bit.ly/PrenatalSpecs, accessed March 3, 2015

For more information on this study, please contact Michelle Casey at mcasey@umn.edu



This study was conducted by the Flex Monitoring Team with funding from the Federal Office of Rural Health Policy (FORHP), Health Resources and Services Administration (HRSA), U.S. Department of Health and Human Services (HHS), under PHS Grant No. U27RH01080. The information, conclusions, and opinions expressed in this document are those of the authors and no endorsement by FORHP, HRSA, or HHS is intended or should be inferred.